Tata Sons-backed biotech startup MedTherapy said it has developed a next-generation CAR-T cell therapy manufacturing platform that can redu...

A new gene editing medicine, VERVE-102, offers hope for millions with heart conditions. Eli Lilly's drug showed significant reductions in b...

A groundbreaking study published in Nature Medicine reveals that the experimental drug Elraglusib, when combined with standard chemotherapy...

India is taking a groundbreaking step forward in the realm of rare disease care with a distinctive approach that champions local ingenuity ...

Sun Pharmaceutical is making its biggest move yet with a $13 billion offer for Organon & Co. This ambitious bid aims to transform the India...

The US has slapped up to 100% tariffs on patented drugs, sparing generics and biosimilars but exposing India’s speciality pharma players. S...

Rocket Pharmaceuticals' shares dropped significantly after gaining FDA approval for Kresladi, a gene therapy for a rare childhood immune di...

The studies published in the New England Journal of Medicine highlight the potential of gene-based drugs in lowering cholesterol levels in ...

The kit is currently being used by a couple of unidentified drug makers in India, said GenePath Diagnostics CEO Nickhil Jakatdar. He said t...

Mapping your entire genetic structure the startup’s GenomeKundli, gives customers an insight on predisposition to more than 100 plus geneti...

BI and Lupin will together develop and commercialise a new drug called MEK inhibitor that will target specific cancer cells and potentially...

New York, June 29 (IANS) Scientists have developed a drug that could partially restore hearing in patients with an inherited form of progre...

Also called colon, rectal or bowel cancer, CRC is the third most common cancer in men and the second in women worldwide.

Growing resistance to malaria drugs in Southeast Asia is caused by a single mutated gene inside the disease-causing parasite, according to ...

The idea was conceived in the 1970s but after that, a large number of clinical trials did not result in a commercial drug.

Ajay Royyuru, who heads the Computational Biology Center at IBM Research, is doing ground-breaking work in personalised, information-based ...

Reliance LifeScience on Wednesday announced the acquisition of a 74% equity stake (1.1 billion shares) in the UK-based biotech firm.